Presentation is loading. Please wait.

Presentation is loading. Please wait.

Switching Breast Cancer Patients with Progressive Bone Metastases to Third- Generation Bisphosphonates: Measuring Impact Using the Functional Assessment.

Similar presentations


Presentation on theme: "Switching Breast Cancer Patients with Progressive Bone Metastases to Third- Generation Bisphosphonates: Measuring Impact Using the Functional Assessment."— Presentation transcript:

1 Switching Breast Cancer Patients with Progressive Bone Metastases to Third- Generation Bisphosphonates: Measuring Impact Using the Functional Assessment of Cancer Therapy-Bone Pain  Reuben Broom, FRACP, Hongyan Du, MS, Mark Clemons, MD, David Eton, PhD, George Dranitsaris, MS, Christine Simmons, FRCP, Wei Ooi, MD, David Cella, PhD  Journal of Pain and Symptom Management  Volume 38, Issue 2, Pages (August 2009) DOI: /j.jpainsymman Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

2 Fig. 1 Scatter plot of FACT-BP score with BPI (worst pain score in last three days). Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman ) Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions


Download ppt "Switching Breast Cancer Patients with Progressive Bone Metastases to Third- Generation Bisphosphonates: Measuring Impact Using the Functional Assessment."

Similar presentations


Ads by Google